Circulating sclerostin is elevated in short-term and reduced in long-term SCI

Bone

Volumn 51, Issue 3, 2012, Pages 600-605

  Battaglino, Ricardo A ^a,b   Sudhakar, Supreetha ^c   Lazzari, Antonio A ^d   Garshick, Eric ^e,f   Zafonte, Ross ^c,g   Morse, Leslie R ^a,c,g  

^a FORSYTH INSTITUTE   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c American Journal of Physical Medicine and Rehabilitation   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Osteoporosis; Rehabilitation medicine; Sclerostin; Spinal cord injury

Indexed keywords

SCLEROSTIN;

ADULT; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL UNLOADING; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; SPINAL CORD INJURY;

ADULT; AGED; AGED, 80 AND OVER; AGING; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SPINAL CORD INJURIES; TIME FACTORS; VITAMIN D;

EID: 84864761121     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.04.019     Document Type: Article

References (19)

1. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007, 5:464-475.
2. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003, 278:24113-24117.
3. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
4. Demirel G., Yilmaz H., Paker N., Onel S. Osteoporosis after spinal cord injury. Spinal Cord 1998, 36:822-825.
5. Jiang S.D., Dai L.Y., Jiang L.S. Osteoporosis after spinal cord injury. Osteoporos Int 2006, 17:180-192.
6. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
7. Lewiecki E.M. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 2011, 11:117-127.
8. Morse L.R., Lazzari A., Battaglino R.A., Stolzmann K., Matthess K., Gagnon D., Davis S., Garshick E. Dual energy X-Ray absorptiometry of the distal femur may be more reliable than the proximal tibia in spinal cord injury. Arch Phys Med Rehabil 2009, 90:827-831.
9. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 2008, 105:20764-20769.
10. Modder U.I., Hoey K.A., Amin S., McCready L.K., Achenbach S.J., Riggs B.L., et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011, 26:373-379.
11. Kirshblum S.C., Memmo P., Kim N., Campagnolo D., Millis S. Comparison of the revised 2000 American Spinal Injury Association classification standards with the 1996 guidelines. Am J Phys Med Rehabil 2002, 81:502-505.
12. Gaudio A., Pennisi P., Bratengeier C., Torrisi V., Lindner B., Mangiafico R.A., et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010, 95:2248-2253.
13. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95:1991-1997.
14. Sutherland M.K., Geoghegan J.C., Yu C., Winkler D.G., Latham J.A. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004, 35:448-454.
15. Cejka D., Jager-Lansky A., Kieweg H., Weber M., Bieglmayer C., Haider D.G., et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012, 27:226-230.
16. Ardawi M.S., Al-Kadi H.A., Rouzi A.A., Qari M.H. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26:2812-2822.
17. Szollar S.M., Martin E.M., Sartoris D.J., Parthemore J.G., Deftos L.J. Bone mineral density and indexes of bone metabolism in spinal cord injury. Am J Phys Med Rehabil 1998, 77(1):28-35.
18. Bauman W.A., Zhang R.L., Morrison N., Spungen A.M. Acute suppression of bone turnover with calcium infusion in persons with spinal cord injury. J Spinal Cord Med 2009, 32(4):398-403.
19. Morse L.R., Lazzari A., Battaglino R.A., Stolzmann K., Matthess K., Gagnon D., et al. Dual energy X-Ray absorptiometry of the distal femur may be more reliable than the proximal tibia in spinal cord injury. Arch Phys Med Rehabil 2009, 90:827-831.